Inotiv, Inc. Common Stock
NOTVInotiv, Inc. (NOTV) is a contract research organization (CRO) that provides research and development services primarily to biopharmaceutical and biotechnology companies. The company specializes in preclinical research, including pharmacology, toxicology, and ADME (absorption, distribution, metabolism, and excretion) testing, supporting drug discovery and development processes. Inotiv operates laboratories across the United States and offers tailored solutions to accelerate the development of new therapies.
Company News
Inotiv achieved 448% revenue growth from fiscal year 2021 to 2024, ranking 182nd on the Deloitte Technology Fast 500â„¢ list for the third consecutive year, highlighting its strategic expansion and client-focused approach in the contract research organization sector.
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: RL) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintaine...
Discover rare investment picks for December 2023 that you might have overlooked from analysts who make less-frequent recommendations. Read more here.
